Tags
- 3
- A
- AbbVie Inc.
- Accelerate
- ADC
- Agent
- Alpha
- An
- Antibody
- Antibody-drug conjugate
- Anticarcinogen
- Approval
- Away
- Axe
- Axes
- Bet
- Big Pharma
- BMS
- Bristol Myer
- Bristol-Myers Squibb
- Cancer
- Candidate
- Cell
- Challenge
- Chasing
- Chemotherapy
- Chief
- Chief Medical Officer
- ClinicalTrials.gov
- Co-development
- Completion
- Completion date
- Conjugate
- Conjugation
- Cut It
- Cytotoxicity
- Data
- Dates
- Deal
- Destruction
- Develop
- Development
- Dose
- Dozen
- Drive
- Dropped A tuning
- Eisai
- End
- Enrollment
- Estimation
- Europe
- Evidence
- Exclusive
- Exclusive right
- Expression
- Externalization
- Fallopian tube
- Fallopian tube cancer
- Farletuzumab
- Genmab
- Health
- High Priority
- ImmunoGen
- Indication
- Japanese
- Land
- Layoff
- Lining
- Listed
- Lung cancer
- Market
- M.D.
- Medical
- Medical Officer
- Meds
- Milestone
- Milestones
- Myer
- Myers Squibb
- Need
- Neoplasm
- No
- Officer
- Ovary
- Over
- Pack
- Pact
- Parts
- Patient
- Payload
- Peritoneum
- Pharma
- Phase
- Phase 1
- PHASE 2
- Phase 2 trial
- Phase 2 trials
- Pipeline
- PLU
- Portfolio
- Portion
- Primary
- Principle
- Principles
- Prioritization
- Priority
- Rationalization
- Receptor
- Recruitment
- Reflection
- Refund
- Research and development
- Rights
- Rival
- Samit Hirawat
- Sell
- Solid
- Spare
- Still
- Strike
- Studie
- Target
- Targeted
- Targets
- The Agent
- The Rival
- The time
- The Tumor
- The world
- Three
- Tissue
- Trial
- Trials
- Tube
- Tumor
- Two-phase
- Unused
- Unveiled
- Upfront
- Walking
- Walking Away
- What
- When
- Win